Evolus, Inc. (EOLS) financial statements (2020 and earlier)

Company profile

Business Address 520 NEWPORT CENTER DRIVE
NEWPORT BEACH, CA 92660
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7493
Cash and cash equivalents3993
Short-term investments35 
Receivables7 
Inventory, net of allowances, customer advances and progress billings10 
Inventory10 
Other undisclosed current assets41
Total current assets:9594
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment1 
Intangible assets, net (including goodwill)8177
Goodwill2121
Intangible assets, net (excluding goodwill)6056
Other noncurrent assets10
Total noncurrent assets:8778
TOTAL ASSETS:183172
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities145
Accounts payable 2
Accrued liabilities 4
Employee-related liabilities3 
Other undisclosed accounts payable and accrued liabilities11 
Debt1 
Other undisclosed current liabilities10 
Total current liabilities:265
Noncurrent Liabilities
Long-term debt and lease obligation7717
Long-term debt, excluding current maturities7317
Operating lease, liability4
Liabilities, other than long-term debt00
Deferred rent credit 0
Deferred income tax liabilities0
Other undisclosed noncurrent liabilities6265
Total noncurrent liabilities:14082
Total liabilities:16687
Stockholders' equity
Stockholders' equity attributable to parent1784
Common stock00
Additional paid in capital216207
Accumulated other comprehensive income0 
Accumulated deficit(199)(123)
Total stockholders' equity:1784
TOTAL LIABILITIES AND EQUITY:183172

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Revenues
(Other undisclosed Revenues)
15 
Cost of revenue
(Cost of Goods and Services Sold)
(4) 
Gross profit:11 
Operating expenses(110)(46)
Operating loss:(99)(46)
Nonoperating income (expense)(3)0
Investment income, nonoperating10
Other nonoperating expense(5) 
Interest and debt expense(0)(1)
Loss from continuing operations before equity method investments, income taxes:(102)(47)
Other undisclosed loss from continuing operations before income taxes(1) 
Loss from continuing operations before income taxes:(103)(47)
Income tax expense (benefit)15(0)
Net loss available to common stockholders, diluted:(88)(47)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(88)(47)
Comprehensive loss:(88)(47)
Other undisclosed comprehensive income, net of tax, attributable to parent0 
Comprehensive loss, net of tax, attributable to parent:(88)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: